Research output per year
Research output per year
Personal profile
Research interests
My interests surround aggressive subgroups of breast cancer, HER2 overexpressed and triple negative breast cancer, some of which disproportionately affect young women with poor prognosis, hence an area yearning for innovative, more effective options.
Clinical interests
Breast cancer, medical oncology, breast health
Fingerprint
Dive into the research topics where Nusayba Bagegni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
Ademuyiwa, F. O., Northfelt, D. W., O’Connor, T., Levine, E., Luo, J., Tao, Y., Hoog, J., Laury, M. L., Summa, T., Hammerschmidt, T., Guo, Z., Frith, A., Weilbaecher, K., Opyrchal, M., Aft, R., Clifton, K., Suresh, R., Bagegni, N., Hagemann, I. S., Iglesia, M. D., & 1 others, Dec 2023, In: npj Breast Cancer. 9, 1, 1.Research output: Contribution to journal › Article › peer-review
Open Access -
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
Davis, A. A., Gerratana, L., Clifton, K., Medford, A. J., Velimirovic, M., Hensing, W. L., Bucheit, L., Shah, A. N., D'Amico, P., Reduzzi, C., Zhang, Q., Dai, C. S., Denault, E. N., Bagegni, N. A., Opyrchal, M., Ademuyiwa, F. O., Bose, R., Gradishar, W. J., Behdad, A., Ma, C. X., & 2 others, Dec 2022, In: EBioMedicine. 86, 104316.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
Kruse, M. L., Kang, I. M., Bagegni, N. A., Howell, W. T., Moore, H. C. F., Bedell, C. H. & Stokoe, C. T., Jun 2022, In: Oncology and Therapy. 10, 1, p. 279-289 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
Bagegni, N. A., Park, H., Kraft, K., O-Toole, M., Gao, F., Waqar, S. N., Ratner, L., Morgensztern, D., Devarakonda, S., Amin, M., Baggstrom, M. Q., Liang, C., Selvaggi, G. & Wang-Gillam, A., Apr 2022, In: Cancer Chemotherapy and Pharmacology. 89, 4, p. 487-497 11 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
Bagegni, N. A., Davis, A. A., Clifton, K. K. & Ademuyiwa, F. O., 2022, In: Breast Cancer: Targets and Therapy. 14, p. 113-123 11 p.Research output: Contribution to journal › Review article › peer-review
Open Access4 Scopus citations